Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
225Ac-FAPI-XT in advanced solid tumors
NCT07135128Phase 1Recruiting
- Sponsor
- ACON Laboratories
- Start
- Oct 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Actinium-225 FAPI-XT in solid tumor (advanced stage), sponsored by ACON Laboratories. Primary endpoints: Treatment emergent adverse events at 2 years and Dose-limiting toxicity at 2 years. Started Oct 2024; status: recruiting.
02
Drugs
Actinium-225 FAPI-XT
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07135128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07135128.